# Diabetes Research Hub — Daily Iteration Report
**Date:** 2026-07-27 (Monday — weekly sweep run)
**Agent:** diabetes-research-iterate (autonomous)

## Summary
Monday run with full weekly PubMed sweep. Four substantive queue items advanced plus credibility sweep and pipeline rebuild. Corpus grew by one paper (new UNVETTED PMID from the sweep). No fabricated data; all claims trace to sources.

## Corpus State
- **Papers:** 286 (272 VETTED / 13 FLAGGED / 1 UNVETTED)
- New this run: **PMID 40696181** — "Disparities in access to and use of diabetes technologies and therapeutics: a narrative review" (added UNVETTED; supports Gap #2; to be vetted next run).

## Work Completed

### 1. Monday weekly PubMed sweep (7 mandated areas)
Result: mostly reaffirmations of already-tracked items; one new PubMed-indexed PMID added.
- **LADA** — only narrative reviews (Rev Colombiana Endo 2026; CCJM 92(12):757). No new primary beta-cell/therapy study.
- **Islet transplant 2026** — Eledon/tegoprubart 12-patient UChicago cohort reaffirmed (all insulin-independent, CNI-free) but STILL conference/IR only, no peer-reviewed publication (tracked, queue item 11).
- **NLRP3 DKD** — MDPI IJMS 27(10):4257 (ferroptosis, preclinical) re-confirmed real via DOI but still not PubMed-indexed. Review PMC12206412 (NLRP3-mediated pyroptosis in DN) added to watch (no confirmed PMID yet).
- **Drug repurposing / beta cell** — verapamil + liraglutide only; nothing new.
- **Verapamil T1D** — CLVer (peds, +30% C-peptide) and Ver-A-T1D (adult, equivocal/underpowered) both already tracked.
- **Dapagliflozin + colchicine** — no such diabetes trial exists; only empagliflozin+colchicine post-STEMI (non-diabetes). SAFEGUARD (dapa+colchicine) already tracked (item 10).
- **Oxidative stress combos** — Nutrition Reviews MA (DOI 10.1093/nutrit/nuaf292) + astaxanthin RCT already tracked; new review PMC12469104 noted as watch.

### 2. Gap #2 (Health Equity, GOLD) — monthly audit
**Verdict: REMAINS GOLD.** New 2026 equity RCTs found but all at behavioral / telehealth / access-incentive level (Annals of Family Medicine Jan 2026 "Incentives and Equity"; ACCTiVATE telehealth-equity RCT, PMC11646453; IDEA SMART trial, PMC11270937), NOT advanced/cell-therapy equity. Narrative review PMID 40696181 documents access disparities in diabetes technologies and T1D immunotherapies. The specific open gap — equity-focused RCTs with hard endpoints in advanced/cell/immunotherapy access — remains unfilled. No promotion/demotion. Next audit ~2026-08-27.

### 3. UNVETTED_NO_PMID re-verify (due today)
MDPI IJMS 27(10):4257 (DOI 10.3390/ijms27104257) and Wiley iid3.70424 both re-confirmed real via DOI but STILL not PubMed-indexed — no retrievable PMID. Both remain UNVETTED_NO_PMID (pmid=PENDING, **not fabricated**). Next re-verify 2026-08-10.

### 4. Path validation — baricitinib_t1d_beta_cell
**REAFFIRMED VALIDATED.** BANDIT phase-2 NEJM result re-confirmed (mixed-meal C-peptide 0.65 vs 0.43 nmol/L/min at 48 wk, n=91). Breakthrough T1D / TrialNet report two phase-3 disease-modifying trials now underway. Rating unchanged (single phase-2 RCT pending phase-3 replication).

## Credibility Sweep — CLEAN
- Fabricated PMIDs (>42,000,000): **0**
- "zero SAEs" / "zero rejection" claims: **0**
- Overstated preclinical language (curative/cure): **0** (only hit is a comment inside verify_before_deploy.py describing what the checker detects).

## Pipeline Rebuild
Offline build/postprocess stages all **[OK]**: healthequity, researchpaths, paperlibrary, extracted, corpus, statistics, postprocess.
Network stages (pmidverify, ingest, validate) not run — sandbox cannot reach PubMed/PMC API (documented limitation, queue item 38 → run on local machine).

## Git / Deployment
Commit + push handled at end of run. **Push remains BLOCKED** in sandbox (no GitHub auth: "could not read Username for https://github.com"). User must run `git push` from local PowerShell. See queue item 0 for lock/auth details. All state changes are saved to working files on disk and persist for the next run.

## Next Run Priorities
1. Vet new UNVETTED paper PMID 40696181.
2. Validate next stalest DISTINCT path (never-dated cluster paths: metformin→nephropathy, calcineurin→islet_transplant, canagliflozin→inflammation).
3. Gap #8, #9, #10, #15 audits due ~2026-08-05.
4. Re-verify MDPI ijms27104257 PubMed indexing on 2026-08-10.
